BioreclamationIVT, a leading provider of biospecimens and related services, has signed a new distribution partnership agreement with Cellaria, LLC.
According to the terms of the agreement, BioreclamationIVT will have exclusive market and distribution rights to Cellaria’s novel cancer cell lines and cancer culture media in the United States and Canada and non-exclusive rights to sell the products globally.
The agreement expands the availability of Cellaria’s offerings to a broader range of potential customers via an established distribution partner with existing relationships inside the biopharmaceutical industry.
Designed to accelerate cancer research, the Cellaria cell models are derived directly from patient tumours with fully consented, fully documented pathological data.
A unique feature of the cell models is their ability to maintain the fidelity of primary cells, with no genetic manipulation, while still offering the long-term reproducibility and scalability seen with traditional tumour cell lines.
In addition to the cell lines, BioreclamationIVT will also distribute Cellaria’s proprietary media, which is specifically formulated to extend in vitro propagation of primary tumour and epithelial cells.
David Deems, President of Cellaria Biosciences, said: “As a trusted partner to leading biopharmaceutical companies, BioreclamationIVT supports our goals of providing oncology researchers with more actionable data during their development of personalised therapeutics.”
“Cellaria products represent an important addition to our rapidly growing disease-state matrices portfolio,” said Jeff Gatz, CEO of BioreclamationIVT.
“This distribution partnership leverages the strengths of both companies and ensures that we will continue to deliver relevant tools and services for our clients focused on disease research.”